Heart Imaging Study to Detect Cardiotoxicity and Risk of Heart Failure in Young Cancer Survivors Treated with Anthracycline Chemotherapy

What this Trial Is About

Researchers are investigating the effects of anthracycline chemotherapies, commonly used to treat pediatric cancer, which carry a risk of heart damage leading to heart failure and early cardiovascular death. The study aims to improve methods for identifying patients at risk before significant heart function changes occur by focusing on imaging markers of cardiac injury and dysfunction. This observational study includes adolescents and young adults with a history of childhood cancer to better understand the cardiotoxic effects of these treatments. Participants will undergo cardiac magnetic resonance imaging MRI to examine heart remodeling, function, and tissue characteristics. Physical activity will also be monitored using a hip-worn accelerometer. Testing will be done at the start of the study and again after at least three years to observe changes over time. During the study, participants will have cardiac MRI scans and physical activity assessments. Researchers will measure left ventricular ejection fraction LVEF over a 3 to 5-year period to evaluate heart function. The study will monitor participants long-term to better predict heart failure risk after cancer treatment, with total participation spanning several years including baseline and follow-up assessments.

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure